End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.15 CNY | +1.59% | +3.32% | -2.25% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.25% | 3.13B | B+ | ||
+29.68% | 681B | C+ | ||
+25.07% | 556B | B | ||
-4.35% | 361B | C+ | ||
+17.65% | 325B | B- | ||
+3.77% | 285B | C+ | ||
+14.68% | 235B | B+ | ||
+4.71% | 199B | B- | ||
-12.43% | 189B | A+ | ||
-3.79% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600380 Stock
- Ratings Joincare Pharmaceutical Group Industry Co.,Ltd.